KFG Wealth Management LLC Buys 82 Shares of Cencora, Inc. (NYSE:COR)

KFG Wealth Management LLC boosted its position in Cencora, Inc. (NYSE:COR) by 3.9% during the 2nd quarter, Holdings Channel.com reports. The firm owned 2,171 shares of the company’s stock after purchasing an additional 82 shares during the period. KFG Wealth Management LLC’s holdings in Cencora were worth $489,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Valeo Financial Advisors LLC boosted its stake in Cencora by 3.4% in the second quarter. Valeo Financial Advisors LLC now owns 1,566 shares of the company’s stock worth $353,000 after buying an additional 51 shares in the last quarter. MJP Associates Inc. ADV boosted its position in Cencora by 3.2% during the second quarter. MJP Associates Inc. ADV now owns 2,372 shares of the company’s stock valued at $534,000 after buying an additional 73 shares during the period. Dynamic Advisor Solutions LLC grew its stake in shares of Cencora by 9.4% during the second quarter. Dynamic Advisor Solutions LLC now owns 1,012 shares of the company’s stock valued at $228,000 after buying an additional 87 shares during the last quarter. Cooper Financial Group increased its holdings in shares of Cencora by 3.2% in the second quarter. Cooper Financial Group now owns 2,920 shares of the company’s stock worth $658,000 after buying an additional 91 shares during the period. Finally, Rise Advisors LLC bought a new stake in shares of Cencora in the 1st quarter valued at about $25,000. 97.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on COR. Robert W. Baird raised their price target on Cencora from $285.00 to $287.00 and gave the stock an “outperform” rating in a research report on Thursday, August 1st. Citigroup raised their target price on shares of Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. StockNews.com upgraded shares of Cencora from a “buy” rating to a “strong-buy” rating in a report on Friday, August 2nd. Wells Fargo & Company raised their price target on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a report on Thursday, August 1st. Finally, SVB Leerink restated an “outperform” rating and issued a $275.00 price objective on shares of Cencora in a research report on Thursday, June 27th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and a consensus target price of $254.57.

Insider Transactions at Cencora

In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the company’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total transaction of $399,991,976.80. Following the transaction, the insider now owns 24,418,171 shares in the company, valued at approximately $5,252,836,945.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Dermot Mark Durcan acquired 500 shares of Cencora stock in a transaction dated Friday, May 24th. The stock was purchased at an average cost of $218.58 per share, for a total transaction of $109,290.00. Following the purchase, the director now directly owns 21,876 shares of the company’s stock, valued at approximately $4,781,656.08. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $215.12, for a total value of $399,991,976.80. Following the completion of the transaction, the insider now directly owns 24,418,171 shares in the company, valued at approximately $5,252,836,945.52. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 6,338,756 shares of company stock worth $1,476,658,274. Corporate insiders own 15.80% of the company’s stock.

Cencora Trading Up 0.6 %

COR stock traded up $1.44 on Friday, reaching $238.11. The company’s stock had a trading volume of 1,013,198 shares, compared to its average volume of 1,384,765. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.53 and a current ratio of 0.89. The business has a fifty day simple moving average of $231.19 and a two-hundred day simple moving average of $232.64. The firm has a market cap of $47.49 billion, a PE ratio of 26.05, a PEG ratio of 1.68 and a beta of 0.45. Cencora, Inc. has a 12-month low of $171.65 and a 12-month high of $247.66.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, topping analysts’ consensus estimates of $3.18 by $0.16. The firm had revenue of $74.20 billion for the quarter, compared to the consensus estimate of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The business’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.92 EPS. As a group, research analysts forecast that Cencora, Inc. will post 13.56 EPS for the current year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 26th. Shareholders of record on Friday, August 9th will be issued a $0.51 dividend. This represents a $2.04 annualized dividend and a yield of 0.86%. The ex-dividend date is Friday, August 9th. Cencora’s dividend payout ratio (DPR) is 22.32%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.